1085458-61-2

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1085458-63-4 10-benzyl-8-oxa-3,10-diazabicyclo[4.3.1]decane 
• 81514-40-1 N-benzyl-7-oxa-9-azabicyclo<3.3.1>nonan-3-one 
• 1085458-59-8 10-benzyl-8-oxa-3,10-diazabicyclo[4.3.1]decan-4-one 

Downstream Products

• 1085458-68-9 tert-butyl 10-[2-(2H-1,2,3-triazol-2-yl)benzoyl]-8-oxa-3,10-diazabicyclo[4.3.1]decane-3-carboxylate 
• 1085458-32-7 3-(6-fluoroquinazolin-2-yl)-10-[2-(2H-1,2,3-triazol-2-yl)benzoyl]-8-oxa-3,10-diazabicyclo[4.3.1]decane 
• 1085458-63-4 10-benzyl-8-oxa-3,10-diazabicyclo[4.3.1]decane 
• 1085458-73-6 (1R,6S)-10-benzyl-8-oxa-3,10-diazabicyclo[4.3.1]decane 
• 1085458-75-8 (1S,6R)-10-benzyl-8-oxa-3,10-diazabicyclo[4.3.1]decane 
• 1085458-70-3 C₁₆H₁₉N₅O₂ 

Relevant academic research and scientific papers

SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF

The present application relates to novel imidazopyridinyl-or imidazopyrimidinyl-substituted, bridged 1,4-diazepane derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring.

OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to oxo bridged diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.